{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:11:49Z","timestamp":1779340309131,"version":"3.51.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that imposes a substantial disease burden in China. As novel therapeutic options emerge, understanding patient preferences has become essential for treatment decision-making. This study aimed to assess treatment preferences and willingness to pay (WTP) among Chinese gMG patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, cross-sectional survey was conducted from March to August 2025 among patients with gMG in China. A discrete choice experiment was used to quantify patient preferences by presenting hypothetical treatment scenarios defined by eight key attributes. A mixed Logit regression model was used to identify preference drivers, and WTP was estimated to reflect the monetary value assigned to changes in treatment attributes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 909 analyzed patients, the mean age was 48.9 \u00b1 13.27 years, and 61.8% were female. Within the selected attribute sets, safety was a key determinant of patient preferences, with consistently favored for lower risks of adverse drug reactions (ADRs) on metabolic diseases, infection, myelosuppression, and liver and kidney function impairment; WTP increased as risk levels decreased. Patients preferred oral administration, followed by subcutaneous injection and intravenous infusion. Infrequent dosing, once every-6-month, weekly or daily, was preferred over 2\u20133 times daily. Faster onset time of action (\u22642 weeks) was favored, and higher out-of-pocket costs were disfavored. Subgroup analyses revealed young patients valued once weekly dosing, subcutaneous injection, and low risk of liver and kidney function impairment than old patients. Patients with high disease burden showed similar preferences for low and moderate ADRs risk. High-income patients favored low ADRs risk, infrequent dosing, subcutaneous injection, and were less sensitive to cost than to low- and medium-income patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large-scale study was the first to investigated treatment preferences and WTP among Chinese patients with gMG. Within the selected attribute sets, patients prioritized safety, infrequent and convenient administration route, affordability, and rapid onset of action. Patients were willing to invest financially in therapies that align with these preferences. Incorporating patient preferences in clinical decision-making and reimbursement policy may improve adherence, reduce disease burden, and enhance quality of life for individuals with gMG in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1795988","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:47:35Z","timestamp":1779338855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China"],"prefix":"10.3389","volume":"17","author":[{"given":"Yafang","family":"Xu","sequence":"first","affiliation":[{"name":"Huashan Rare Disease Center and Department of Nursing, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University\/West China School of Nursing, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Nursing, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Nursing, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Xiao","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Nursing, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwen","family":"Ni","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Nursing, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University\/West China School of Nursing, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyue","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University\/West China School of Nursing, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University\/West China School of Nursing, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyu","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University\/West China School of Nursing, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University\/West China School of Nursing, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University\/West China School of Nursing, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingxian","family":"He","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2505722","article-title":"Myasthenia gravis-redemption for B-cell depletion","volume":"392","author":"Wolfe","year":"2025","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103669","article-title":"Towards personalized management of myasthenia gravis phenotypes: From the role of multi-omics to the emerging biomarkers and therapeutic targets","volume":"23","author":"Balistreri","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00821-y","article-title":"Treatment preferences of neurologists in generalized myasthenia gravis: a conjoint analysis study","volume":"14","author":"Querol","year":"2025","journal-title":"Neurol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","article-title":"Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis","volume":"19","author":"Salari","year":"2021","journal-title":"J Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","article-title":"New and emerging biological therapies for myasthenia gravis: a focused review for clinical decision-making","volume":"39","author":"Gerischer","year":"2025","journal-title":"BioDrugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.02.019","article-title":"A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies","volume":"19","author":"Ho","year":"2016","journal-title":"Value Health"},{"key":"B9","unstructured":"Technical Guidelines for the Design of Patient-Centered Drug Clinical Trials (Trial Version)\n          \n          2023"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7436.360","article-title":"Discrete choice experiments in health care","volume":"328","author":"Ryan","year":"2004","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70081","article-title":"Patient and care partner perspectives and preferences related to myasthenia gravis treatment: A qualitative study","volume":"7","author":"Yung","year":"2024","journal-title":"Health Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70230","article-title":"Design of and early insights from a generalized myasthenia gravis patient engagement research council","volume":"7","author":"Geonnotti","year":"2024","journal-title":"Health Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0001051448.28270.45","article-title":"Patient preferences for generalized myasthenia gravis treatment profiles: results of a web-based survey","volume":"103","author":"Karen","year":"2024","journal-title":"Neurol J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113694-20250120-00041","article-title":"Chinese guideline for diagnosis and treatment of myasthenia gravis (2025 edition)","volume":"58","year":"2025","journal-title":"Chin J Neurol"},{"key":"B15","unstructured":"2022 China Myasthenia Gravis Patient Health Report\n          \n          2024"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy","volume":"31","author":"Sacc\u00e0","year":"2024","journal-title":"Eur J Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00032-6","article-title":"Myasthenia gravis: subgroup classifications","volume":"15","author":"Li","year":"2016","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci Ther"},{"key":"B19","unstructured":"The situation of residents' income and consumption expenditure in 2024\n          \n          2025"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278","article-title":"Social disadvantages associated with myasthenia gravis and its treatment: a multicenter cross-sectional study","volume":"7","author":"Nagane","year":"2017","journal-title":"BMJ Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.11.008","article-title":"Evaluation of clinical features and prognosis of myasthenia gravis in adults based on the age of onset: a retrospective study from a single center of 30 years MG registry","volume":"27","author":"Fatma","year":"2022","journal-title":"Neurol Asia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111586","article-title":"Clinical heterogeneity, treatment patterns, and outcomes of advanced-age-onset myasthenia gravis in China: a retrospective cohort study","volume":"141","author":"Ji","year":"2025","journal-title":"J Clin Neurosci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalized myasthenia gravis (MycarinG): a randomized, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2475075","article-title":"Economic burden of myasthenia gravis in China: a nationwide registry-based study","volume":"41","author":"Yu","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-023-02187-0","article-title":"Current management of myasthenia gravis in Belgium: a single-center experience","volume":"123","author":"Mercelis","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CND.0000000000000133","article-title":"A review of azathioprine-associated hepatotoxicity and myelosuppression in myasthenia gravis","volume":"18","author":"Jack","year":"2016","journal-title":"J Clin Neuromuscul Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012604","article-title":"Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the swedish GEMG study","volume":"97","author":"Petersson","year":"2021","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10902-1","article-title":"Causes of symptom dissatisfaction in patients with generalized myasthenia gravis","volume":"269","author":"Andersen","year":"2022","journal-title":"J Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalized myasthenia gravis (RAISE): a randomized, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1212\/WNL.0000000000206306","article-title":"Patient preferences for myasthenia gravis treatments: A discrete-choice experiment","volume":"102","author":"Mansfield","year":"2024","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40290-023-00509-4","article-title":"Eliciting exploratory patient preference data: a case study in a rare disease","volume":"38","author":"Ho","year":"2024","journal-title":"Pharmaceut Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251347283","article-title":"Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalized myasthenia gravis: a phase IIIb, open-label study","volume":"18","author":"Freimer","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B33","unstructured":"Inquiry of basic information for overseas-produced drugs"},{"key":"B34","unstructured":"Inquiry of basic information for overseas-produced drugs"},{"key":"B35","unstructured":"Inquiry of basic information for overseas-produced drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.12173\/j.issn.1005-0698.202408007","article-title":"Efgartigimod alfa in the treatment of generalized myasthenia gravis: a rapid health technology assessment","volume":"10","author":"Huang","year":"2024","journal-title":"Chin J Pharmacoepidemiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2022.10.008","article-title":"Patient access to orphan drugs covered by medical insurance in China: real-world evidence from patient survey","volume":"34","author":"Wang","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1186\/s12889-025-23831-9","article-title":"Multi-criteria decision analysis of value evaluation of rare disease medical insurance drugs in China","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Public Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12939-024-02137-z","article-title":"Analysis of affordability differences for rare diseases in China: a comparison across disease types and regions","volume":"23","author":"Chen","year":"2024","journal-title":"Int J Equity Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1186\/s12889-022-14244-z","article-title":"Investigating patients' preferences for new anti-diabetic drugs to inform public health insurance coverage decisions: a discrete choice experiment in China","volume":"22","author":"Geng","year":"2022","journal-title":"BMC Public Health"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1795988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:47:59Z","timestamp":1779338879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1795988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1795988"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1795988","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1795988"}}